Department of Cardiology, Aarhus University Hospital, Denmark; Danish Centre for Particle Therapy, Aarhus University Hospital, Denmark.
Department of Cardiology, Aarhus University Hospital, Denmark.
Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):186-195. doi: 10.1016/j.ijrobp.2021.03.053. Epub 2021 May 19.
Cardiac implantable electronic devices (CIED) are sensitive to scattered secondary neutrons from proton beam irradiation. This experimental in vitro study investigated risk of CIED errors during pencil beam proton therapy.
We used 62 explanted CIEDs from 4 manufacturers; 49 CIEDs were subjected to a simulated clinical protocol with daily 2 Gy relative biological effectiveness fractions prescribed to the phantom. Devices were located at 3 different lateral distances from the spread-out Bragg peak to investigate the risk of permanent or temporary device errors. Additionally, 13 devices with leads connected were monitored live during consecutive irradiations to investigate the risk of noise, over- or undersense, pace inhibition, and inappropriate shock therapy.
We detected 61 reset errors in 1728 fractions, and all except 1 CIED were reprogrammed to normal function. All, except 1 reset, occurred in devices from the same manufacturer. These were successfully reprogrammed to normal function. The 1 remaining CIED was locked in permanent safety mode. Secondary neutron dose, as estimated by Monte Carlo simulations, was found to significantly increase the odds of CIED resets by 55% per mSv. Clinically significant battery depletion was observed in 5 devices. We observed no noise, over- or undersense, pace inhibition, or inappropriate shock therapy during 362 fractions of live monitoring.
Reprogrammable CIED reset was the most commonly observed malfunction during proton therapy, and reset risk depended on secondary neutron exposure. The benefits of proton therapy are expected to outweigh the risk of CIED malfunctioning for most patients.
心脏植入式电子设备(CIED)对质子束照射产生的散射次级中子敏感。本实验体外研究调查了笔形束质子治疗过程中 CIED 错误的风险。
我们使用了来自 4 个制造商的 62 个已植入的 CIED;49 个 CIED 接受了模拟临床方案的治疗,每天给予 2 Gy 的相对生物有效剂量,剂量被规定至体模的扩展布拉格峰。将设备放置在离扩展布拉格峰的 3 个不同的横向距离处,以调查永久性或暂时性设备错误的风险。此外,还对 13 个带有连接导联的设备进行了连续照射的实时监测,以调查噪声、过感或欠感、起搏抑制和不适当的电击治疗的风险。
我们在 1728 个分次照射中检测到 61 个重置错误,除 1 个 CIED 外,所有设备均被重新编程为正常功能。除 1 个重置错误外,所有错误均发生在来自同一制造商的设备中。这些设备成功地重新编程为正常功能。其余 1 个 CIED 则被锁定在永久性安全模式。通过蒙特卡罗模拟估算的次级中子剂量发现,CIED 重置的几率每增加 1 mSv 就会增加 55%。在 5 个设备中观察到了明显的电池电量耗竭。在 362 个分次照射的实时监测中,我们没有观察到噪声、过感或欠感、起搏抑制或不适当的电击治疗。
在质子治疗过程中,可重新编程的 CIED 重置是最常见的故障,重置风险取决于次级中子的暴露。对于大多数患者来说,质子治疗的益处预计将超过 CIED 故障的风险。